Abstract
We evaluated clinically and in ex-vivo with adult mongrel dogs newly developed hollow fiber membrane plasma separater (TP-50) whose membrane was composed of polymer alloy. The sieving co-efficient in total protein exceeded 0.9 and that in beta-lipoprotein was maintained to be above 0.8 during plasma separation. Plasma flux was also stable during the treatments. White blood cell and platelet counts showed slight decrease in the initial phase of plasmapheresis, but in that point, there were no differences between TP-50 and the commercially available control membrane plasma separater. Little clinical side effects such as hemolysis or hyrotenson were observed. We conclude that this plasma separator has sufficient efficacy and blood compatibility for plasma separation and can be widely applicable for clinical usage.
